Codagenix Announces Late-Breaking Presentation of Positive Clinical Immunogenicity Data For COVID-19 Vaccine Candidate CoviLiv™ at IDWeek 2023
FARMINGDALE, N.Y., Oct. 11, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.
- Data show that participants who received two doses of 5x106 PFU of CoviLiv showed robust induction of both humoral and cellular immune responses.
- T cell reactivity was demonstrated to be specific for multiple viral antigens beyond the frequently mutating spike protein.
- The vaccine was designed using the Codagenix platform technology that re-codes the genetic material of a virus – converting the virus from a disease-causing pathogen into a stable and safe, live-attenuated vaccine.
- SIIPL, the world's largest vaccine manufacturer by number of doses produced and sold globally, is manufacturing the vaccine for this clinical study.